Cargando…

MSLN Gene Silencing Has an Anti-Malignant Effect on Cell Lines Overexpressing Mesothelin Deriving from Malignant Pleural Mesothelioma

Genes involved in the carcinogenetic mechanisms underlying malignant pleural mesothelioma (MPM) are still poorly characterized. So far, mesothelin (MSLN) has aroused the most interest. It encodes for a membrane glycoprotein, frequently over-expressed in various malignancies such as MPM, and ovarian...

Descripción completa

Detalles Bibliográficos
Autores principales:	Melaiu, Ombretta, Stebbing, Justin, Lombardo, Ylenia, Bracci, Elisa, Uehara, Norihisa, Bonotti, Alessandra, Cristaudo, Alfonso, Foddis, Rudy, Mutti, Luciano, Barale, Roberto, Gemignani, Federica, Giamas, Georgios, Landi, Stefano
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3897543/ https://www.ncbi.nlm.nih.gov/pubmed/24465798 http://dx.doi.org/10.1371/journal.pone.0085935

Ejemplares similares

Correction: MSLN gene silencing has an anti-malignant effect on cell lines overexpressing mesothelin deriving from malignant pleural mesothelioma
por: Melaiu, Ombretta, et al.
Publicado: (2017)

Variation rs2235503 C > A Within the Promoter of MSLN Affects Transcriptional Rate of Mesothelin and Plasmatic Levels of the Soluble Mesothelin-Related Peptide
por: Silvestri, Roberto, et al.
Publicado: (2020)

Deregulation of miRNAs in malignant pleural mesothelioma is associated with prognosis and suggests an alteration of cell metabolism
por: De Santi, Chiara, et al.
Publicado: (2017)

Identification of Overexpressed Genes in Malignant Pleural Mesothelioma
por: Morani, Federica, et al.
Publicado: (2021)

Inhibition of the platelet-derived growth factor receptor beta (PDGFRB) using gene silencing, crenolanib besylate, or imatinib mesylate hampers the malignant phenotype of mesothelioma cell lines
por: Melaiu, Ombretta, et al.
Publicado: (2017)

Comparative proteomic analysis of malignant pleural mesothelioma: Focusing on the biphasic subtype
por: Giusti, Laura, et al.
Publicado: (2016)

Liquid Biopsies from Pleural Effusions and Plasma from Patients with Malignant Pleural Mesothelioma: A Feasibility Study
por: Moretti, Gabriele, et al.
Publicado: (2021)

Big and Free Fractions of Gamma-Glutamyltransferase: New Diagnostic Biomarkers for Malignant Mesothelioma?
por: Foddis, Rudy, et al.
Publicado: (2022)

Comparison of the Diagnostic Accuracy of the MSLN Gene Products, Mesothelin and Megakaryocyte Potentiating Factor, as Biomarkers for Mesothelioma in Pleural Effusions and Serum
por: Creaney, Jenette, et al.
Publicado: (2013)

Comparison of fibulin-3 and mesothelin as markers in malignant mesothelioma
por: Creaney, Jenette, et al.
Publicado: (2014)

Anti-Mesothelin CAR T cell therapy for malignant mesothelioma
por: Castelletti, Laura, et al.
Publicado: (2021)

Comprehensive immunohistochemical study of mesothelin (MSLN) using different monoclonal antibodies 5B2 and MN-1 in 1562 tumors with evaluation of its prognostic value in malignant pleural mesothelioma
por: Inaguma, Shingo, et al.
Publicado: (2017)

Role of Prosaposin and Extracellular Sulfatase Sulf-1 Detection in Pleural Effusions as Diagnostic Biomarkers of Malignant Mesothelioma
por: Zallocco, Lorenzo, et al.
Publicado: (2022)

Soluble Mesothelin-Related Peptides Levels in Patients with Malignant Mesothelioma
por: Franko, Alenka, et al.
Publicado: (2012)

Pleural Fluid Mesothelin as an Adjunct to the Diagnosis of Pleural Malignant Mesothelioma
por: Creaney, Jenette, et al.
Publicado: (2014)

Evaluation of Soluble Mesothelin-related Peptides and MSLN Genetic Variability in Asbestos-related Diseases
por: Goricar, Katja, et al.
Publicado: (2020)

EIF4G1 and RAN as Possible Drivers for Malignant Pleural Mesothelioma
por: Dell’Anno, Irene, et al.
Publicado: (2020)

Association of MiR-126 with Soluble Mesothelin-Related Peptides, a Marker for Malignant Mesothelioma
por: Santarelli, Lory, et al.
Publicado: (2011)

Drug-repositioning screening identified fludarabine and risedronic acid as potential therapeutic compounds for malignant pleural mesothelioma
por: Dell’Anno, Irene, et al.
Publicado: (2020)

Level of mesothelin expression can indicate the prognosis of malignant pleural mesothelioma
por: Feng, Feifei, et al.
Publicado: (2020)

Prognostic significance of soluble mesothelin in malignant pleural mesothelioma: a meta-analysis
por: Tian, Long, et al.
Publicado: (2017)

Increased Levels of C-C Chemokine RANTES in Asbestos Exposed Workers and in Malignant Mesothelioma Patients from an Hyperendemic Area
por: Comar, Manola, et al.
Publicado: (2014)

Tissue expression of lactate transporters (MCT1 and MCT4) and prognosis of malignant pleural mesothelioma (brief report)
por: Dell’Anno, Irene, et al.
Publicado: (2020)

One Third of Malignant Pleural Mesothelioma Shows High Immunohistochemical Expression of MSLN or CXCR4 Which Indicates Potent Candidates for Endo-Radiotherapy
por: Hager, Thomas, et al.
Publicado: (2023)

Diagnostic values of soluble mesothelin-related peptides for malignant pleural mesothelioma: updated meta-analysis
por: Cui, Ai, et al.
Publicado: (2014)

Hitting the Bull’s-Eye: Mesothelin’s Role as a Biomarker and Therapeutic Target for Malignant Pleural Mesothelioma
por: Yeo, Dannel, et al.
Publicado: (2021)

A Drug Screening Revealed Novel Potential Agents against Malignant Pleural Mesothelioma
por: Dell’Anno, Irene, et al.
Publicado: (2022)

A serum mesothelin level is a prognostic indicator for patients with malignant mesothelioma in routine clinical practice
por: Linch, Mark, et al.
Publicado: (2014)

Midkine is a potential novel marker for malignant mesothelioma with different prognostic and diagnostic values from mesothelin
por: Ak, Guntulu, et al.
Publicado: (2017)

Combination of MiR-103a-3p and Mesothelin Improves the Biomarker Performance of Malignant Mesothelioma Diagnosis
por: Weber, Daniel G., et al.
Publicado: (2014)

Diagnostic value of soluble mesothelin-related peptides in pleural effusion for malignant pleural mesothelioma: An updated meta-analysis
por: Gao, Ruiyue, et al.
Publicado: (2019)

Mesothelin expression remodeled the immune-matrix tumor microenvironment predicting the risk of death in patients with malignant pleural mesothelioma
por: Qualiotto, Aline Nery, et al.
Publicado: (2023)

Ranpirnase and its potential for the treatment of unresectable malignant mesothelioma
por: Porta, Camillo, et al.
Publicado: (2008)

A Glimpse in the Future of Malignant Mesothelioma Treatment
por: Pezzicoli, Gaetano, et al.
Publicado: (2021)

Hyaluronan and N-ERC/Mesothelin as Key Biomarkers in a Specific Two-Step Model to Predict Pleural Malignant Mesothelioma
por: Mundt, Filip, et al.
Publicado: (2013)

A Novel Panel of Serum Biomarkers for MPM Diagnosis
por: Bonotti, A., et al.
Publicado: (2017)

Antimeningococcal Vaccination Coverage Among Healthcare Workers in an Italian University Hospital
por: Gattini, Vittorio, et al.
Publicado: (2021)

Metformin Antagonizes Ovarian Cancer Cells Malignancy Through MSLN Mediated IL-6/STAT3 Signaling
por: Yang, Xu, et al.
Publicado: (2021)

Cancer antigen profiling for malignant pleural mesothelioma immunotherapy: expression and coexpression of mesothelin, cancer antigen 125, and Wilms tumor 1
por: Eguchi, Takashi, et al.
Publicado: (2017)

Switching off malignant mesothelioma: exploiting the hypoxic microenvironment
por: Nabavi, Noushin, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_joih7ans4ge3obetp86c1gmspf